ArticleAnalytical and bioanalytical chemistry2026
MWCNT-Au-Pt hybrid nanocomposite-based electrochemical immunosensor for FGF-2 detection: a novel strategy for anxiety disorder diagnosis.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The accurate diagnosis of anxiety disorders remains challenging, as current detection methods primarily rely on subjective questionnaires. In this study, a novel electrochemical biosensor for the detection of fibroblast growth factor-2 (FGF-2), a biomarker associated with anxiety disorders, was developed for the first time. The sensing principle was based on monitoring the impedimetric signal changes generated by the interaction between anti-FGF-2 and the FGF-2 antigen, using a carbon screen-printed electrode as the transducer. To enhance the sensitivity and overall performance of the biosensor, a multi-walled carbon nanotube-gold-platinum (MWCNT-Au-Pt) hybrid nanocomposite was incorporated into the immunosensor structure. Critical parameters-including the amount of MWCNT-Au-Pt, the concentration, incubation time, and temperature of anti-FGF-2, as well as the incubation time and temperature for the anti-FGF-2/FGF-2 interaction-were systematically optimized. Under optimized conditions, the developed impedimetric FGF-2 immunosensor exhibited a linear response in the range of 10-100 ng/mL, with a limit of detection of 1.01 ng/mL and a limit of quantification of 3.10 ng/mL. The specificity of the sensor was confirmed in the presence of potential interfering substances. For real sample analysis, human saliva samples (n = 30) were diluted appropriately and spiked with FGF-2 at concentrations of 20, 50, and 75 ng/mL. The obtained recovery values demonstrated that the developed impedimetric FGF-2 immunosensor is highly suitable for real-sample applications and holds significant potential as a reliable tool for the detection of anxiety disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.